SBTX News and Press, Silverback Therapeutics Inc. From 05/17/22

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and othe...

Silverback Therapeutics press release (NASDAQ:SBTX): Q1 GAAP EPS of -$0.70 misses by $0.03. CEO comment: “We believe that activating the immune response is an important component of a functional cure and may be combined with treatments that target the HBV life cycle to improve durabili...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and othe...

Silverback Therapeutics press release (NASDAQ:SBTX): FY GAAP EPS of -$2.56. Company statement: As of December 31, 2021, Silverback reported cash, cash equivalents, restricted cash, and investments of $319.1 million, compared to cash and cash equivalents of $386.6 million at December 31, 2020,...

Announcing its 4Q 2021 results, the clinical-stage biotech, Silverback Therapeutics (NASDAQ:SBTX) announced on Thursday that the company decided to discontinue its SBT6050 and SBT6290 clinical oncology programs. The Seattle, Washington-based Silverback (SBTX) will instead focus its resources ...

- Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 ...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 28, 2021) - Faruqi & Faruqi, LLP, a leading national securities law fi...